Literature DB >> 1905014

Immunogenicity of an engineered internal image antibody.

R Billetta1, M R Hollingdale, M Zanetti.   

Abstract

We engineered an antibody expressing in the third complementarity-determining region of its heavy chain variable region a "foreign" epitope, the repetitive tetrapeptide Asn-Ala-Asn-Pro (NANP) of the circumsporozoite protein of Plasmodium falciparum parasite, one of the etiologic agents of malaria in humans. A monoclonal antibody to P. falciparum specific for the (NANP)n amino acid sequence bound to the engineered antibody, and a synthetic (NANP)3 peptide blocked this interaction. Immunization of rabbits and mice with the engineered antibody resulted in the elicitation of a humoral response to (NANP)3 synthetic peptide and P. falciparum parasite. In mice, in which immunity to the (NANP)n epitope is highly restricted by immune response genes, antibodies were induced in responder and nonresponder haplotypes of the major histocompatibility complex. Rabbit antibodies efficiently inhibited the in vitro invasion of cultured liver cells by P. falciparum parasite. Collectively, this study indicates that immunity to malaria in the absence of the parasite can be induced using antibody variable regions engineered to mimic the parasite's molecular structure. In general terms, the results suggest that antibody (idiotype) mimicry of an exogenous antigen is possible and may only require a discrete stretch of identity between the two molecules. The implication for the preparation of antibody-based vaccines and idiotype regulation of immunity are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905014      PMCID: PMC51736          DOI: 10.1073/pnas.88.11.4713

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Reshaping human antibodies: grafting an antilysozyme activity.

Authors:  M Verhoeyen; C Milstein; G Winter
Journal:  Science       Date:  1988-03-25       Impact factor: 47.728

2.  Use of anti-idiotypic antibodies as cell-surface receptor probes.

Authors:  K Sege; P A Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

3.  Idiotypic regulation of the immune system by the induction of antibodies against anti-idiotypic antibodies.

Authors:  J Urbain; M Wikler; J D Franssen; C Collignon
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

4.  Towards a network theory of the immune system.

Authors:  N K Jerne
Journal:  Ann Immunol (Paris)       Date:  1974-01

5.  Idiotypic-anti-idiotypic regulation of antibody synthesis in rabbits.

Authors:  P A Cazenave
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

6.  Association of H-2 types with genetic control of immune responsiveness to IgA allotypes in the mouse.

Authors:  R Lieberman; W Humphrey
Journal:  Proc Natl Acad Sci U S A       Date:  1971-10       Impact factor: 11.205

7.  Reshaping human antibodies for therapy.

Authors:  L Riechmann; M Clark; H Waldmann; G Winter
Journal:  Nature       Date:  1988-03-24       Impact factor: 49.962

8.  Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.

Authors:  D A Herrington; D F Clyde; G Losonsky; M Cortesia; J R Murphy; J Davis; S Baqar; A M Felix; E P Heimer; D Gillessen
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

9.  Do antibodies recognize amino acid side chains of protein antigens independently of the carbon backbone?

Authors:  V H Van Cleave; C W Naeve; D W Metzger
Journal:  J Exp Med       Date:  1988-06-01       Impact factor: 14.307

10.  Idiotype-anti-idiotype regulation. I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones.

Authors:  C A Bona; E Heber-Katz; W E Paul
Journal:  J Exp Med       Date:  1981-04-01       Impact factor: 14.307

View more
  11 in total

1.  The principle of delivery of T cell epitopes to antigen-presenting cells applied to peptides from influenza virus, ovalbumin, and hen egg lysozyme: implications for peptide vaccination.

Authors:  I B Rasmussen; E Lunde; T E Michaelsen; B Bogen; I Sandlie
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-21       Impact factor: 11.205

2.  Regulation of CAT: Cationic amino acid transporter gene expression.

Authors:  C L Macleod; D K Kakuda
Journal:  Amino Acids       Date:  1996-06       Impact factor: 3.520

3.  Immunogenicity of a contiguous T-B synthetic epitope of the A/PR/8/34 influenza virus.

Authors:  T D Brumeanu; S Casares; A Bot; S Bot; C A Bona
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Epitope-specific tolerance induction with an engineered immunoglobulin.

Authors:  E T Zambidis; D W Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

5.  Modifying specificity of antidigoxin antibodies using insertional mutagenesis.

Authors:  Rustem A Krykbaev; Panayota Tsantili; Philip D Jeffrey; Michael N Margolies
Journal:  Protein Sci       Date:  2002-12       Impact factor: 6.725

6.  Active immunity against the CD4 receptor by using an antibody antigenized with residues 41-55 of the first extracellular domain.

Authors:  P Lanza; R Billetta; S Antonenko; M Zanetti
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

7.  Antibodies designed as effective cancer vaccines.

Authors:  R L Metheringham; V A Pudney; B Gunn; M Towey; I Spendlove; L G Durrant
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

8.  Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif.

Authors:  M Zanetti; G Filaci; R H Lee; P del Guercio; F Rossi; R Bacchetta; F Stevenson; V Barnaba; R Billetta
Journal:  EMBO J       Date:  1993-11       Impact factor: 11.598

9.  Genetic control of anti-idiotypic vaccination against coronavirus infection.

Authors:  M W Yu; S Lemieux; P J Talbot
Journal:  Eur J Immunol       Date:  1996-12       Impact factor: 5.532

10.  Antigenized antibodies expressing Vbeta8.2 TCR peptides immunize against rat experimental allergic encephalomyelitis.

Authors:  Cristina Musselli; Svetlana Daverio-Zanetti; Maurizio Zanetti
Journal:  J Immune Based Ther Vaccines       Date:  2004-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.